AstraZeneca(AZN) - 2025 Q2 - Earnings Call Presentation

Financial Performance - Total Revenue increased by 11% to $28045 million in H1 2025[9, 21] - Core EPS increased by 17% in H1 2025[9, 22] - Product Sales reached $26670 million in H1 2025, representing 95% of Total Revenue[21, 22] - Alliance Revenue contributed $1293 million to Total Revenue in H1 2025, accounting for 5%[21, 22] - Net cash inflow from operating activities increased by 27% in H1 2025[31] Pipeline and Approvals - 19 new approvals were obtained in key regions[9] - 12 positive Phase III readouts were achieved[9] - First Phase III data was reported for 5 NMEs[9] - Readouts across 2025 represent combined >$10 billion opportunity[14] Segment Performance - Oncology Total Revenue reached $120 billion in H1 2025, a 16% increase[36, 37] - BioPharmaceuticals Total Revenue was $66 billion in H1 2025, up by 10%[47, 48] - Rare Disease Total Revenue amounted to $43 billion in H1 2025, a 3% increase[58, 59] Geographical Distribution - US accounted for 43% of Total Revenue in H1 2025, amounting to $11955 million[12] - Europe contributed 21% of Total Revenue in H1 2025, totaling $5825 million[12] - China represented 13% of Total Revenue in H1 2025, with $3515 million[12]